Company Description
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of chronic inflammatory and immune-mediated conditions.
Its lead program, repibresib gel (VYN201), is a topically administered small molecule pan bromodomain (BD) extra-terminal (BET) inhibitor soft drug that address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.
The company also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control and chronic management of immune-mediated inflammatory conditions.
The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020.
VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
| Country | United States |
| Founded | 2003 |
| IPO Date | Jan 25, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | David Domzalski |
Contact Details
Address: 685 Route 202/206 N, Suite 301 Bridgewater, New Jersey 08807 United States | |
| Phone | 800 775 7936 |
| Website | vynetherapeutics.com |
Stock Details
| Ticker Symbol | VYNE |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001566044 |
| CUSIP Number | 92941V209 |
| ISIN Number | US92941V3087 |
| Employer ID | 45-3757789 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| David T. Domzalski | Chief Executive Officer, President and Director |
| Dr. Iain A. Stuart Ph.D. | Chief Scientific Officer |
| Mutya Harsch J.D. | General Counsel, Chief Legal Officer and Company Secretary |
| Tyler Zeronda CPA | Chief Financial Officer and Treasurer |
| Dr. Subhashis Banerjee M.D. | Senior Vice President of Clinical Development |
| Dr. Darrell S. Rigel FAAD, M.D. | Consultant |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 6, 2025 | 10-K | Annual Report |
| Mar 6, 2025 | 8-K | Current Report |
| Jan 13, 2025 | 8-K | Current Report |
| Dec 23, 2024 | 8-K | Current Report |
| Dec 19, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Dec 12, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | ARS | Filing |
| Nov 12, 2024 | DEF 14A | Other definitive proxy statements |
| Nov 7, 2024 | 10-Q | Quarterly Report |